{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:48:36Z","timestamp":1783648116479,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The medical care of patients with myositis is a great challenge in clinical practice.\u00a0This is due to the rarity of these disease, the complexity of diagnosis and\u00a0management as well as the lack of systematic analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Therefore, the aim of this project was to obtain an overview of the current care of myositis patients in Germany and to evaluate epidemiological trends in recent years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In collaboration with BARMER Insurance, retrospective analysis of outpatient and inpatient data from an average of approximately 8.7 million insured patients between January 2005 and December 2019 was performed using ICD-10 codes for myositis for identification of relevant data. In addition, a comparative analysis was performed between myositis patients and an age-matched comparison group from other populations insured by BARMER.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>45,800 BARMER-insured individuals received a diagnosis of myositis during the observation period, with a relatively stable prevalence throughout. With regard to comorbidities, a significantly higher rate of cardiovascular disease as well as neoplasm was observed compared to the control group within the BARMER-insured population. In addition, myositis patients suffer more frequently from psychiatric disorders, such as depression and somatoform disorders. However, the ICD-10 catalogue only includes the specific coding of \u201cdermatomyositis\u201d and \u201cpolymyositis\u201d and thus does not allow for a sufficient analysis of all idiopathic inflammatory myopathies subtypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The current data provide a comprehensive epidemiological analysis of myositis in Germany, highlighting the multimorbidity of myositis patients. This underlines the need for multidisciplinary management. However, the ICD-10 codes currently still in use do not allow for specific analysis of the subtypes of myositis. The upcoming ICD-11 coding may improve future analyses in this regard.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42466-022-00226-4","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T07:03:04Z","timestamp":1672297384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Myositis in Germany: epidemiological insights over 15\u00a0years from 2005 to 2019"],"prefix":"10.1186","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-2277","authenticated-orcid":false,"given":"Marc","family":"Pawlitzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Masanneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Willison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesa","family":"Regner-Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"L\u2019hoest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"226_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/10408363.2021.2000584","volume":"59","author":"KI Tsamis","year":"2021","unstructured":"Tsamis, K. I., Boutsoras, C., Kaltsonoudis, E., et al. (2021). Clinical features and diagnostic tools in idiopathic inflammatory myopathies. Critical Reviews in Clinical Laboratory Sciences, 59, 219\u2013240.","journal-title":"Critical Reviews in Clinical Laboratory Sciences"},{"issue":"3","key":"226_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/art.41964","volume":"74","author":"M Casal-Dominguez","year":"2021","unstructured":"Casal-Dominguez, M., Pinal-Fernandez, I., Pak, K., et al. (2021). Performance of the 2017 EULAR\/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis & Rheumatology, 74(3), 508\u2013517.","journal-title":"Arthritis & Rheumatology"},{"key":"226_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg, I. E., Fujimoto, M., Vencovsky, J., et al. (2021). Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 7, 86.","journal-title":"Nature Reviews Disease Primers"},{"key":"226_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/rheumatology\/key343","volume":"58","author":"MJS Parker","year":"2019","unstructured":"Parker, M. J. S., Oldroyd, A., Roberts, M. E., et al. (2019). The performance of the European League Against Rheumatism\/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. Rheumatology (Oxford), 58, 468\u2013475.","journal-title":"Rheumatology (Oxford)"},{"key":"226_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","volume":"20","author":"V Leclair","year":"2018","unstructured":"Leclair, V., & Lundberg, I. E. (2018). New myositis classification criteria\u2014What we have learned since Bohan and Peter. Current Rheumatology Reports, 20, 18.","journal-title":"Current Rheumatology Reports"},{"key":"226_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis, C. V., & Aggarwal, R. (2018). Treatment in myositis. Nature Reviews Rheumatology, 14, 279\u2013289.","journal-title":"Nature Reviews Rheumatology"},{"key":"226_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00296-020-04634-0","volume":"40","author":"K Albrecht","year":"2020","unstructured":"Albrecht, K., Huscher, D., Callhoff, J., et al. (2020). Trends in idiopathic inflammatory myopathies: Cross-sectional data from the German National Database. Rheumatology International, 40, 1639\u20131647.","journal-title":"Rheumatology International"},{"key":"226_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1055\/a-0884-5633","volume":"38","author":"P Korsten","year":"2019","unstructured":"Korsten, P., Rademacher, J.-G., Seitz, C. S., et al. (2019). Interdisziplin\u00e4re Fallkonferenzen als Chance f\u00fcr Myositis-Patienten? Nervenheilkunde, 38, 337\u2013380.","journal-title":"Nervenheilkunde"},{"key":"226_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s00392-020-01723-9","volume":"109","author":"M Seiffert","year":"2020","unstructured":"Seiffert, M., Brunner, F. J., Remmel, M., et al. (2020). Temporal trends in the presentation of cardiovascular and cerebrovascular emergencies during the COVID-19 pandemic in Germany: An analysis of health insurance claims. Clinical Research in Cardiology, 109, 1540\u20131548.","journal-title":"Clinical Research in Cardiology"},{"key":"226_CR10","first-page":"481","volume":"118","author":"J Diers","year":"2021","unstructured":"Diers, J., Acar, L., Baum, P., et al. (2021). Fewer operations for cancer in Germany during the first wave of COVID-19 in 2020\u2014A cohort study and time-series analysis. Deutsches \u00c4rzteblatt International, 118, 481\u2013482.","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"226_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","volume":"54","author":"A Meyer","year":"2015","unstructured":"Meyer, A., Meyer, N., Schaeffer, M., Gottenberg, J. E., Geny, B., & Sibilia, J. (2015). Incidence and prevalence of inflammatory myopathies: A systematic review. Rheumatology (Oxford), 54, 50\u201363.","journal-title":"Rheumatology (Oxford)"},{"key":"226_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/ard.2008.093161","volume":"68","author":"S Bernatsky","year":"2009","unstructured":"Bernatsky, S., Joseph, L., Pineau, C. A., et al. (2009). Estimating the prevalence of polymyositis and dermatomyositis from administrative data: Age, sex and regional differences. Annals of the Rheumatic Diseases, 68, 1192\u20131196.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"226_CR13","doi-asserted-by":"publisher","first-page":"e0261983","DOI":"10.1371\/journal.pone.0261983","volume":"16","author":"IM Carey","year":"2021","unstructured":"Carey, I. M., Banchoff, E., Nirmalananthan, N., et al. (2021). Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data. PLoS ONE, 16, e0261983.","journal-title":"PLoS ONE"},{"key":"226_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/14397595.2013.844308","volume":"24","author":"A Ohta","year":"2014","unstructured":"Ohta, A., Nagai, M., Nishina, M., Tomimitsu, H., & Kohsaka, H. (2014). Prevalence and incidence of polymyositis and dermatomyositis in Japan. Modern Rheumatology, 24, 477\u2013480.","journal-title":"Modern Rheumatology"},{"key":"226_CR15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug, C., Garen, T., Bitter, H., et al. (2015). Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; Data from a large and unselected Norwegian cohort. Annals of the Rheumatic Diseases, 74, 1551\u20131556.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"226_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/annrheumdis-2012-eular.2904","volume":"71","author":"TN Tran","year":"2013","unstructured":"Tran, T. N., Steffey, A., & Caspard, H. (2013). FRI0447 Epidemiology of idiopathic inflammatory myopathies in England\u2014A database analysis. Annals of the Rheumatic Diseases, 71, 465\u2013466.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"226_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.55563\/clinexprheumatol\/o5nvgv","volume":"39","author":"I Gonzalez-Mazon","year":"2021","unstructured":"Gonzalez-Mazon, I., Sanchez-Bilbao, L., Martin-Varillas, J. L., et al. (2021). Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: A 3-year study of 102 cases from a single centre. Clinical and Experimental Rheumatology, 39, 612\u2013620.","journal-title":"Clinical and Experimental Rheumatology"},{"key":"226_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217018","volume":"81","author":"T Nguyen","year":"2022","unstructured":"Nguyen, T., Maria, A. T. J., Ladhari, C., et al. (2022). Rheumatic disorders associated with immune checkpoint inhibitors: What about myositis? An analysis of the WHO\u2019s adverse drug reactions database. Annals of the Rheumatic Diseases, 81, e32.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"226_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","volume":"100","author":"M Seki","year":"2019","unstructured":"Seki, M., Uruha, A., Ohnuki, Y., et al. (2019). Inflammatory myopathy associated with PD-1 inhibitors. Journal of Autoimmunity, 100, 105\u2013113.","journal-title":"Journal of Autoimmunity"},{"key":"226_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","volume":"33","author":"J Tanboon","year":"2020","unstructured":"Tanboon, J., Uruha, A., Stenzel, W., & Nishino, I. (2020). Where are we moving in the classification of idiopathic inflammatory myopathies? Current Opinion in Neurology, 33, 590\u2013603.","journal-title":"Current Opinion in Neurology"},{"key":"226_CR21","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","volume":"75","author":"K Mariampillai","year":"2018","unstructured":"Mariampillai, K., Granger, B., Amelin, D., et al. (2018). Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurology, 75, 1528\u20131537.","journal-title":"JAMA Neurology"},{"key":"226_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill, C. L., Zhang, Y., Sigurgeirsson, B., et al. (2001). Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet, 357, 96\u2013100.","journal-title":"Lancet"},{"key":"226_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3899\/jrheum.140566","volume":"42","author":"Z Yang","year":"2015","unstructured":"Yang, Z., Lin, F., Qin, B., Liang, Y., & Zhong, R. (2015). Polymyositis\/dermatomyositis and malignancy risk: A metaanalysis study. Journal of Rheumatology, 42, 282\u2013291.","journal-title":"Journal of Rheumatology"},{"key":"226_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/1756-185X.14046","volume":"24","author":"Y Li","year":"2021","unstructured":"Li, Y., Jia, X., Sun, X., et al. (2021). Risk factors for cancer-associated myositis: A large-scale multicenter cohort study. International Journal of Rheumatic Diseases, 24, 268\u2013273.","journal-title":"International Journal of Rheumatic Diseases"},{"key":"226_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker, J. B., Vencovsky, J., Wang, G., et al. (2018). The EuroMyositis registry: An international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases, 77, 30\u201339.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"226_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/biom12010111","volume":"12","author":"AH Opinc","year":"2022","unstructured":"Opinc, A. H., & Makowska, J. S. (2022). Update on malignancy in myositis-well-established association with unmet needs. Biomolecules, 12, 111.","journal-title":"Biomolecules"},{"key":"226_CR27","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","volume":"60","author":"AGS Oldroyd","year":"2021","unstructured":"Oldroyd, A. G. S., Allard, A. B., Callen, J. P., et al. (2021). A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford), 60, 2615\u20132628.","journal-title":"Rheumatology (Oxford)"},{"key":"226_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2015.09.016","volume":"74","author":"J Achtman","year":"2016","unstructured":"Achtman, J., Kling, M. A., Feng, R., Okawa, J., & Werth, V. P. (2016). A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. Journal of the American Academy of Dermatology, 74, 377\u2013379.","journal-title":"Journal of the American Academy of Dermatology"},{"key":"226_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00296-020-04779-y","volume":"41","author":"R Naveen","year":"2021","unstructured":"Naveen, R., Rathore, U., Agarwal, V., & Gupta, L. (2021). Characteristics and outcomes of overlap myositis: A comparative multigroup cohort study in adults from the MyoCite cohort. Rheumatology International, 41, 551\u2013563.","journal-title":"Rheumatology International"},{"key":"226_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.170541","volume":"45","author":"TJ Doyle","year":"2018","unstructured":"Doyle, T. J., Dhillon, N., Madan, R., et al. (2018). Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: A multicenter retrospective case review. Journal of Rheumatology, 45, 841\u2013850.","journal-title":"Journal of Rheumatology"},{"key":"226_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","volume":"56","author":"S Fasano","year":"2017","unstructured":"Fasano, S., Gordon, P., Hajji, R., Loyo, E., & Isenberg, D. A. (2017). Rituximab in the treatment of inflammatory myopathies: A review. Rheumatology (Oxford), 56, 26\u201336.","journal-title":"Rheumatology (Oxford)"},{"key":"226_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12016-016-8530-2","volume":"52","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia, S., Oddis, C. V., & Aggarwal, R. (2017). Modern therapies for idiopathic inflammatory myopathies (IIMs): Role of biologics. Clinical Reviews in Allergy and Immunology, 52, 81\u201387.","journal-title":"Clinical Reviews in Allergy and Immunology"},{"key":"226_CR33","unstructured":"Schilling, M. K. R.: Kodierleitfaden Neurologie. https:\/\/dgn.org\/wp-content\/uploads\/2020\/05\/Kodierleitfaden_Neurologie_2020_final.pdf"},{"key":"226_CR34","unstructured":"Organization WH. ICD-11. https:\/\/icd.who.int\/browse11\/l-m\/en"},{"key":"226_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/BOR.0000000000000549","volume":"30","author":"A Oldroyd","year":"2018","unstructured":"Oldroyd, A., & Chinoy, H. (2018). Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 30, 606\u2013613.","journal-title":"Current Opinion in Rheumatology"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-022-00226-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T07:08:01Z","timestamp":1672297681000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-022-00226-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["226"],"URL":"https:\/\/doi.org\/10.1186\/s42466-022-00226-4","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethic approval is needed due to the nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MP received research funding from Novartis and honoraria for lecturing from ArgenX, Biogen, Janssen and Merck. His research is founded by the German Multiple Sclerosis Society North Rhine-Westphalia (DMSG). LA no conflict of interest. LM received compensation for an educational internship at Biogen. AW no conflict of interest. LRN no conflict of interest. CN no conflict of interest. HL no conflict of interest. UM no conflict of interest. JS has received payments for advisory boards, speaker\u2019s honoraria, travel expenses or research projects from Abcuro, Alnylam, Argenx, Biotest, CSL Behring, Euroimmun, Janssen, Kezar, LFB, Novartis, Octapharma and UCB. SGM received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut f\u00fcr Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. TR reports grants from German Ministry of Education, Science, Research and Technology, grants and personal fees from Sanofi-Aventis and Alexion; personal fees from Biogen Idec, Roche and Teva; personal fees and nonfinancial support from Merck Serono, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}